Circular Genomics

Executive Summary

Circular Genomics is pioneering precision medicine for psychiatric and neurological disorders using a novel circular RNA (circRNA) diagnostic platform. Founded in 2018 and based in San Diego, the company seeks to address the significant unmet need for objective, molecular-based diagnosis and treatment selection in mental health. Circular RNAs are stable, tissue-specific molecules that can serve as biomarkers for conditions like depression, bipolar disorder, and schizophrenia, which currently rely on subjective symptom assessment. The company's approach leverages circRNA signatures to improve diagnostic accuracy and guide therapy selection, potentially reducing trial-and-error prescribing. While still in early private stage with no disclosed funding or pipeline, the science is compelling: circRNAs resistance to degradation and regulatory roles make them attractive biomarkers. However, the company faces typical early-stage risks including validation, regulatory pathway, and competition from other liquid biopsy/neuroscience diagnostics. If successful, Circular Genomics could transform psychiatric care, but proof-of-concept clinical data and funding are critical near-term milestones.

Upcoming Catalysts (preview)

• Q2 2026Series A Funding Announcement70% success
• Q4 2026Initial Clinical Validation Data (e.g., depression biomarker study)50% success
• Q1 2027Strategic Partnership with a Major Pharma or Diagnostics Company40% success